The Effect of Pembrolizumab Plus Platinum-based Chemotherapy on the Progression-free Survival of Non-small-cell Lung Cancer with a High PD-L1 Expression and Large Baseline Tumor Size

DOI Web Site 15 References
  • Fukushiro Yuki
    Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital
  • Takayama Yusuke
    Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital
  • Kakumoto Shinji
    Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital
  • Sumii Masahiko
    Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital
  • Mishima Shohei
    Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital
  • Masuda Ken
    Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital
  • Shoda Hiroyasu
    Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital
  • Iwamoto Yasuo
    Department of Oncology, Hiroshima City Hiroshima Citizens Hospital

Bibliographic Information

Other Title
  • 総腫瘍径の大きいPD-L1高発現の非小細胞肺癌に対するペムブロリズマブとプラチナ製剤併用療法による無増悪生存期間の延長効果

Search this article

Abstract

<p>Background/Aim. Both pembrolizumab monotherapy and PD-1/PD-L1 inhibitor plus platinum-based chemotherapy are recommended for the first-line treatment of advanced non-small-cell lung cancer (NSCLC) with a high PD-L1 expression. However, which therapy is more useful in clinical practice is unclear. We examined the efficacy and safety of each therapy based on the clinical experience at our hospital. Study Design. We retrospectively reviewed 55 NSCLC patients with a high PD-L1 expression between March 2017 and September 2020. Of these 55 patients, 34 underwent pembrolizumab monotherapy (monotherapy), and 21 underwent pembrolizumab plus platinum-based chemotherapy (combination therapy) as their initial treatment. Results. The median progression-free survival (PFS) for patients who underwent combination therapy was longer than that for patients who underwent monotherapy (median: 9.2 vs. 7.7 months) (p=0.762), but there were no significant differences between the groups. In addition, the response rate tended to be higher and the proportion of PD cases lower in the combination group than in the monotherapy group in patients with a large baseline tumor size (BTS). Conclusion. Combination therapy may be more effective than monotherapy for NSCLC with a high PD-L1 expression, especially in cases with a large BTS.</p>

Journal

  • Haigan

    Haigan 61 (4), 289-296, 2021-08-20

    The Japan Lung Cancer Society

References(15)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top